Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Stock Competitors & Peer Comparison
See ALNY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALNY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALNY | $248.68 | +0.47% | 33.3B | 44.81 | $5.55 | N/A |
| VRTX | $515.44 | +0.17% | 130.8B | 27.09 | $19.03 | N/A |
| REGN | $781.49 | -1.48% | 80.5B | 17.13 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $984.39 | +0.04% | 61.2B | 88.84 | $11.08 | N/A |
| MRNA | $143.97 | +5.38% | 57.1B | -17.67 | -$8.15 | N/A |
| RVMDW | $11.29 | +2.08% | 44.2B | -1.28 | -$8.82 | N/A |
| RVMD | $203.77 | +0.21% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $346.51 | +1.38% | 37B | 61.01 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ALNY vs VRTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, VRTX has a market cap of 130.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while VRTX trades at $515.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas VRTX's P/E ratio is 27.09. In terms of profitability, ALNY's ROE is +0.94%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALNY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ALNY vs REGN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while REGN trades at $781.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas REGN's P/E ratio is 17.13. In terms of profitability, ALNY's ROE is +0.94%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ALNY vs VRNA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALNY's ROE is +0.94%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ALNY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ALNY vs ARGX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ARGX has a market cap of 61.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ARGX trades at $984.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ARGX's P/E ratio is 88.84. In terms of profitability, ALNY's ROE is +0.94%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ALNY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ALNY vs MRNA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MRNA has a market cap of 57.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MRNA trades at $143.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MRNA's P/E ratio is -17.67. In terms of profitability, ALNY's ROE is +0.94%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ALNY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ALNY vs RVMDW Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RVMDW has a market cap of 44.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RVMDW trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ALNY is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ALNY vs RVMD Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RVMD trades at $203.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RVMD's P/E ratio is -23.10. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ALNY is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ALNY vs SGEN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALNY's ROE is +0.94%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALNY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
ALNY vs ONC Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ONC has a market cap of 37B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ONC trades at $346.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ONC's P/E ratio is 61.01. In terms of profitability, ALNY's ROE is +0.94%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ALNY vs ROIV Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ROIV has a market cap of 29.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ROIV trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ROIV's P/E ratio is -38.82. In terms of profitability, ALNY's ROE is +0.94%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ALNY is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ALNY vs INSM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, INSM has a market cap of 28B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while INSM trades at $129.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas INSM's P/E ratio is -31.49. In terms of profitability, ALNY's ROE is +0.94%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ALNY is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ALNY vs INCY Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while INCY trades at $121.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas INCY's P/E ratio is 16.33. In terms of profitability, ALNY's ROE is +0.94%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ALNY is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ALNY vs BNTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BNTX trades at $96.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BNTX's P/E ratio is -12.54. In terms of profitability, ALNY's ROE is +0.94%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ALNY is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ALNY vs UTHR Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, UTHR has a market cap of 21.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while UTHR trades at $497.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas UTHR's P/E ratio is 17.79. In terms of profitability, ALNY's ROE is +0.94%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ALNY is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ALNY vs BGNE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALNY's ROE is +0.94%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
ALNY vs GMAB Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, GMAB has a market cap of 19.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while GMAB trades at $32.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas GMAB's P/E ratio is 24.47. In terms of profitability, ALNY's ROE is +0.94%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ALNY vs DNA-WT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ALNY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ALNY vs ASND Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ASND trades at $263.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ASND's P/E ratio is -108.89. In terms of profitability, ALNY's ROE is +0.94%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ALNY is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ALNY vs NBIX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while NBIX trades at $156.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas NBIX's P/E ratio is 22.57. In terms of profitability, ALNY's ROE is +0.94%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ALNY is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ALNY vs JAZZ Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while JAZZ trades at $245.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas JAZZ's P/E ratio is 9.16. In terms of profitability, ALNY's ROE is +0.94%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ALNY is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ALNY vs BBIO Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BBIO trades at $72.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BBIO's P/E ratio is -19.37. In terms of profitability, ALNY's ROE is +0.94%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ALNY is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ALNY vs EXEL Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while EXEL trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas EXEL's P/E ratio is 16.03. In terms of profitability, ALNY's ROE is +0.94%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ALNY is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ALNY vs SMMT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while SMMT trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas SMMT's P/E ratio is -15.67. In terms of profitability, ALNY's ROE is +0.94%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALNY is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ALNY vs HALO Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while HALO trades at $107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas HALO's P/E ratio is 20.00. In terms of profitability, ALNY's ROE is +0.94%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ALNY is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ALNY vs BMRN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BMRN trades at $65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BMRN's P/E ratio is 31.58. In terms of profitability, ALNY's ROE is +0.94%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ALNY is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ALNY vs KRTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALNY's ROE is +0.94%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALNY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ALNY vs MDGL Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MDGL trades at $534.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MDGL's P/E ratio is -41.76. In terms of profitability, ALNY's ROE is +0.94%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ALNY is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ALNY vs ARWR Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ARWR has a market cap of 11.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ARWR trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ARWR's P/E ratio is -36.82. In terms of profitability, ALNY's ROE is +0.94%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ALNY is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ALNY vs AXSM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while AXSM trades at $220.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas AXSM's P/E ratio is -57.64. In terms of profitability, ALNY's ROE is +0.94%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ALNY is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check AXSM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ALNY vs TECH Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TECH trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TECH's P/E ratio is 37.18. In terms of profitability, ALNY's ROE is +0.94%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ALNY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ALNY vs RNAM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALNY's ROE is +0.94%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALNY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RNAM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ALNY vs KRYS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while KRYS trades at $347.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas KRYS's P/E ratio is 43.48. In terms of profitability, ALNY's ROE is +0.94%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALNY is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ALNY vs RXDX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALNY's ROE is +0.94%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ALNY vs PTGX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PTGX trades at $148.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PTGX's P/E ratio is 143.86. In terms of profitability, ALNY's ROE is +0.94%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ALNY is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ALNY vs KYMR Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while KYMR trades at $114.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas KYMR's P/E ratio is -35.92. In terms of profitability, ALNY's ROE is +0.94%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ALNY is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ALNY vs PRAX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PRAX trades at $334.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PRAX's P/E ratio is -25.88. In terms of profitability, ALNY's ROE is +0.94%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ALNY is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PRAX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ALNY vs CYTK Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CYTK trades at $73.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CYTK's P/E ratio is -10.22. In terms of profitability, ALNY's ROE is +0.94%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ALNY is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ALNY vs NUVL Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALNY's ROE is +0.94%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALNY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check NUVL's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ALNY vs IONS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while IONS trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas IONS's P/E ratio is -31.52. In terms of profitability, ALNY's ROE is +0.94%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ALNY is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ALNY vs CRNX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ALNY's ROE is +0.94%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALNY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ALNY vs IMGN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALNY's ROE is +0.94%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALNY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
ALNY vs ABVX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ABVX trades at $118.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ABVX's P/E ratio is -62.19. In terms of profitability, ALNY's ROE is +0.94%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALNY is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ABVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ALNY vs TXG Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TXG has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TXG trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TXG's P/E ratio is -116.25. In terms of profitability, ALNY's ROE is +0.94%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ALNY is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TXG's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ALNY vs PCVX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PCVX trades at $59.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PCVX's P/E ratio is -7.79. In terms of profitability, ALNY's ROE is +0.94%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ALNY is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ALNY vs BPMC Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALNY's ROE is +0.94%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ALNY vs APGE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas APGE's P/E ratio is -31.19. In terms of profitability, ALNY's ROE is +0.94%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ALNY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ALNY vs IBRX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while IBRX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas IBRX's P/E ratio is -8.15. In terms of profitability, ALNY's ROE is +0.94%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ALNY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ALNY vs TGTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TGTX trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TGTX's P/E ratio is 19.53. In terms of profitability, ALNY's ROE is +0.94%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ALNY is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ALNY vs CERE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALNY's ROE is +0.94%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALNY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ALNY vs TWST Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TWST has a market cap of 7.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TWST trades at $127.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TWST's P/E ratio is -57.31. In terms of profitability, ALNY's ROE is +0.94%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ALNY is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ALNY vs SYRE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while SYRE trades at $90.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas SYRE's P/E ratio is -46.46. In terms of profitability, ALNY's ROE is +0.94%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ALNY is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ALNY vs IMVT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while IMVT trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas IMVT's P/E ratio is -13.25. In terms of profitability, ALNY's ROE is +0.94%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ALNY is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
ALNY vs MTSR Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALNY's ROE is +0.94%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALNY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ALNY vs RYTM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RYTM trades at $104.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RYTM's P/E ratio is -33.67. In terms of profitability, ALNY's ROE is +0.94%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ALNY is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ALNY vs BLTE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while BLTE trades at $173.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas BLTE's P/E ratio is -92.94. In terms of profitability, ALNY's ROE is +0.94%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ALNY is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ALNY vs CAI Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CAI trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CAI's P/E ratio is 68.39. In terms of profitability, ALNY's ROE is +0.94%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ALNY is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CAI's competition here
Merus N.V. (NASDAQ: MRUS)
ALNY vs MRUS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALNY's ROE is +0.94%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ALNY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ALNY vs ACLX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALNY's ROE is +0.94%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALNY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ALNY vs SRRK Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while SRRK trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas SRRK's P/E ratio is -16.06. In terms of profitability, ALNY's ROE is +0.94%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ALNY is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ALNY vs RETA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALNY's ROE is +0.94%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALNY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
ALNY vs CGON Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CGON trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CGON's P/E ratio is -26.90. In terms of profitability, ALNY's ROE is +0.94%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ALNY is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ALNY vs CNTA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALNY's ROE is +0.94%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALNY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ALNY vs TVTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TVTX trades at $66.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TVTX's P/E ratio is -147.04. In terms of profitability, ALNY's ROE is +0.94%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ALNY is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ALNY vs MIRM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MIRM trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MIRM's P/E ratio is -6.75. In terms of profitability, ALNY's ROE is +0.94%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ALNY is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ALNY vs DNTH Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while DNTH trades at $106.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas DNTH's P/E ratio is -25.59. In terms of profitability, ALNY's ROE is +0.94%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ALNY is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ALNY vs COGT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while COGT trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas COGT's P/E ratio is -15.83. In terms of profitability, ALNY's ROE is +0.94%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ALNY is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ALNY vs LGND Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while LGND trades at $284.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas LGND's P/E ratio is 31.23. In terms of profitability, ALNY's ROE is +0.94%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ALNY is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ALNY vs XENE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while XENE trades at $58.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas XENE's P/E ratio is -12.48. In terms of profitability, ALNY's ROE is +0.94%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ALNY is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check XENE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ALNY vs CDTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALNY's ROE is +0.94%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ALNY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ALNY vs ORKA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ORKA trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ORKA's P/E ratio is -47.62. In terms of profitability, ALNY's ROE is +0.94%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ALNY is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
ALNY vs ABCM Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALNY's ROE is +0.94%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALNY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ABCM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ALNY vs PTCT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PTCT trades at $66.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PTCT's P/E ratio is -28.35. In terms of profitability, ALNY's ROE is +0.94%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ALNY is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PTCT's competition here
Erasca, Inc. (NASDAQ: ERAS)
ALNY vs ERAS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ERAS trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ERAS's P/E ratio is -17.08. In terms of profitability, ALNY's ROE is +0.94%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ALNY is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ERAS's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ALNY vs ISEE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALNY's ROE is +0.94%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALNY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ALNY vs APLS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALNY's ROE is +0.94%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALNY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ALNY vs DFTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while DFTX trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ALNY is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ALNY vs CRSP Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CRSP trades at $51.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CRSP's P/E ratio is -10.87. In terms of profitability, ALNY's ROE is +0.94%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ALNY is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ALNY vs EWTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while EWTX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas EWTX's P/E ratio is -24.00. In terms of profitability, ALNY's ROE is +0.94%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ALNY is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ALNY vs TERN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALNY's ROE is +0.94%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALNY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ALNY vs ACAD Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ACAD trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ACAD's P/E ratio is 12.54. In terms of profitability, ALNY's ROE is +0.94%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ALNY is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ALNY vs FOLD Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALNY's ROE is +0.94%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALNY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ALNY vs AKRO Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALNY's ROE is +0.94%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALNY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ALNY vs ALPN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALNY's ROE is +0.94%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALNY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ALNY vs PBLS Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PBLS trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PBLS's P/E ratio is -41.91. In terms of profitability, ALNY's ROE is +0.94%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ALNY is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
ALNY vs OPT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALNY's ROE is +0.94%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALNY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ALNY vs PRTC Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ALNY's ROE is +0.94%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ALNY is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PRTC's competition here
Veradermics, Incorporated (NYSE: MANE)
ALNY vs MANE Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MANE trades at $98.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MANE's P/E ratio is -31.52. In terms of profitability, ALNY's ROE is +0.94%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ALNY is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ALNY vs RLAY Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RLAY trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RLAY's P/E ratio is -12.02. In terms of profitability, ALNY's ROE is +0.94%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ALNY is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ALNY vs MRTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALNY's ROE is +0.94%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALNY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ALNY vs CELC Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CELC trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CELC's P/E ratio is -19.41. In terms of profitability, ALNY's ROE is +0.94%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ALNY is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ALNY vs ELVN Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ELVN trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ELVN's P/E ratio is -32.53. In terms of profitability, ALNY's ROE is +0.94%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ALNY is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ELVN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ALNY vs ADPT Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while ADPT trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas ADPT's P/E ratio is -59.02. In terms of profitability, ALNY's ROE is +0.94%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ALNY is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ALNY vs TNGX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TNGX trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TNGX's P/E ratio is -28.65. In terms of profitability, ALNY's ROE is +0.94%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ALNY is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ALNY vs CPRX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ALNY's ROE is +0.94%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALNY is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ALNY vs IOVA Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while IOVA trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas IOVA's P/E ratio is -11.78. In terms of profitability, ALNY's ROE is +0.94%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ALNY is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IOVA's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ALNY vs TLX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while TLX trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas TLX's P/E ratio is 117.85. In terms of profitability, ALNY's ROE is +0.94%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ALNY is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ALNY vs RYZB Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALNY's ROE is +0.94%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALNY is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RYZB's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ALNY vs VKTX Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while VKTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas VKTX's P/E ratio is -6.86. In terms of profitability, ALNY's ROE is +0.94%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ALNY is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check VKTX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ALNY vs CBAY Comparison September 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 33.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALNY is priced at $248.68 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 44.81, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALNY's ROE is +0.94%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALNY is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CBAY's competition here